Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2021 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups

First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety dataCompany to expand FX201 low dose and mid dose cohorts...
February 01, 2021 09:00 ET | Source: Flexion Therapeutics, Inc.

National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®

CHICAGO and BURLINGTON, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise...
January 13, 2021 07:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results

Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 millionFull-year 2020 net sales estimated to be...
January 07, 2021 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
December 07, 2020 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
December 04, 2020 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock...
November 06, 2020 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...
November 05, 2020 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
November 04, 2020 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
October 29, 2020 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right